![Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet](https://www.thelancet.com/cms/asset/43c19cc3-58f4-41c4-8c50-86f1f443c0fb/gr1.jpg)
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet
![Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19 | Australian Government Department of Health and Aged Care Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19 | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2022/05/expanded-atagi-recommendations-on-winter-covid-19-booster-doses-for-people-at-increased-risk-of-severe-covid-19.png?itok=JQbSJjDd)
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19 | Australian Government Department of Health and Aged Care
![Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel — United States, 2021–22 | MMWR Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel — United States, 2021–22 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7142a2_COVID19FluVax_IMAGE_21Oct22_1200x675.jpg?_=83012)
Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel — United States, 2021–22 | MMWR
![Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health](https://publichealth.jhu.edu/sites/default/files/styles/social_image/public/2023-02/bivalent-vaccine-g1422104879.jpg?itok=mgeH3XVw)
Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health
HSE Ireland on X: "We are putting plans in place after the latest advice from NIAC regarding a second #COVIDVaccine booster for the recommended groups. Appointments are not open for a second
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)